| Literature DB >> 25196387 |
Swadesh K Das1,2,3, Mitchell E Menezes1, Shilpa Bhatia1, Xiang-Yang Wang1,2,3, Luni Emdad1,2,3, Devanand Sarkar1,2,3, Paul B Fisher1,2,3.
Abstract
Gene therapy, which involves replacement of a defective gene with a functional, healthy copy of that gene, is a potentially beneficial cancer treatment approach particularly over chemotherapy, which often lacks selectivity and can cause non-specific toxicity. Despite significant progress pre-clinically with respect to both enhanced targeting and expression in a tumor-selective manner several hurdles still prevent success in the clinic, including non-specific expression, low-efficiency delivery and biosafety. Various innovative genetic approaches are under development to reconstruct vectors/transgenes to make them safer and more effective. Utilizing cutting-edge delivery technologies, gene expression can now be targeted in a tissue- and organ-specific manner. With these advances, gene therapy is poised to become amenable for routine cancer therapy with potential to elevate this methodology as a first line therapy for neoplastic diseases. This review discusses recent advances in gene therapy and their impact on a pre-clinical and clinical level.Entities:
Mesh:
Year: 2015 PMID: 25196387 PMCID: PMC4363073 DOI: 10.1002/jcp.24791
Source DB: PubMed Journal: J Cell Physiol ISSN: 0021-9541 Impact factor: 6.384